Novarifyn® (NP432) is an antibacterial peptide with a number of key benefits over conventional antibiotic therapies and the clear potential to succeed where existing treatments for a number of bacterial infections, including those caused by MRSA, P. aeruginosa and C. difficile are failing.

Importantly, Novarifyn has no or at least very low risk of acquired resistance development in target pathogens compared to conventional antibiotics. This is due to a rapid, membrane-lysing bactericidal mechanism of action.

Clinical and Commercial Development

Novarifyn is a preclinical asset.

Novarifyn is potently and rapidly bactericidal in vitro against clinically and economically important bacterial pathogens – including multi drug resistant Gram negative and Gram positive species

Novarifyn is well-tolerated and demonstrated efficacy in in vivo infection models.

NovaBiotics has developed NP432 from the same technology platform as NP213 (Novexatin) and NP339 (Novamycin) and so the route to clinic anticipated for this novel peptide antibacterial has already been significantly de-risked.

Molecule Class and Formulation

Novarifyn can be formulated to facilitate topical, parenteral, and aerosol delivery and is not sensitive to physiologic salt or pH conditions.

Mechanism of Action

Novarifyn has a mechanism of action based on membrane perturbation and lysis which rapidly kills bacteria (not merely inhibiting growth).

NP423 is active against a range of difficult to treat pathogens including MRSA, P. aeruginosa,C. difficile, A. baumannii and K. pnuemoniae.